Toolkit/Z7-E78-ABE

Z7-E78-ABE

Construct Pattern·Research·Since 2025

Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.

Summary

The resulting Z7-E78-ABE variant not only achieved a 5.76-fold increase compared to WT AtCas9 and expanded PAM recognition, while enabling editing in primary human T cells, which was not observed with WT AtCas9.

Usefulness & Problems

Why this is useful

Z7-E78-ABE is an AtCas9-derived adenine base editor that combines loop engineering with structure-guided point mutations. It improves activity and broadens PAM recognition relative to WT AtCas9.; adenine base editing; expanded PAM recognition; editing in primary human T cells

Source:

Z7-E78-ABE is an AtCas9-derived adenine base editor that combines loop engineering with structure-guided point mutations. It improves activity and broadens PAM recognition relative to WT AtCas9.

Source:

adenine base editing

Source:

expanded PAM recognition

Source:

editing in primary human T cells

Problem solved

It improves AtCas9-based base editing performance and enables editing in primary human T cells where WT AtCas9 did not show editing in the abstract.; insufficient AtCas9-derived base editing activity; lack of detectable editing in primary human T cells with WT AtCas9

Source:

It improves AtCas9-based base editing performance and enables editing in primary human T cells where WT AtCas9 did not show editing in the abstract.

Source:

insufficient AtCas9-derived base editing activity

Source:

lack of detectable editing in primary human T cells with WT AtCas9

Problem links

insufficient AtCas9-derived base editing activity

Literature

It improves AtCas9-based base editing performance and enables editing in primary human T cells where WT AtCas9 did not show editing in the abstract.

Source:

It improves AtCas9-based base editing performance and enables editing in primary human T cells where WT AtCas9 did not show editing in the abstract.

lack of detectable editing in primary human T cells with WT AtCas9

Literature

It improves AtCas9-based base editing performance and enables editing in primary human T cells where WT AtCas9 did not show editing in the abstract.

Source:

It improves AtCas9-based base editing performance and enables editing in primary human T cells where WT AtCas9 did not show editing in the abstract.

Published Workflows

Loop engineering of AtCas9 for effective and broad genome editing.

2025

Objective: Optimize thermophilic Cas9 scaffolds for more effective and broader genome editing in mammalian cells using loop engineering and combinatorial engineering.

Why it works: The abstract links improved performance to loop substitution that preserves high binding affinity under magnesium-limiting conditions and to a stable compact conformation, then further boosts activity by combining loop engineering with structure-guided point mutations.

improved RNP-DNA interactions under magnesium limitationstable compact protein conformationloop substitution from mesophilic to thermophilic Cas9 orthologsbiochemical assaymolecular dynamics simulationstructure-guided point mutation combination

Stages

  1. 1.
    Loop substitution design and variant generation(library_design)

    This stage creates loop-engineered Cas9 variants as the core optimization strategy.

    Selection: Substitute surface-exposed loops of thermophilic AtCas9 with counterparts from mesophilic Nme1Cas9.

  2. 2.
    Biochemical mechanistic characterization(functional_characterization)

    This stage tests a mechanistic explanation for improved activity in a condition described as a common constraint in mammalian cells.

    Selection: Assess Mg2+-dependent RNP-DNA interactions and binding affinity under magnesium-limiting condition.

  3. 3.
    Conformational modeling(secondary_characterization)

    This stage provides structural-mechanistic interpretation for the engineered variant's improved behavior.

    Selection: Use molecular dynamics simulations to assess whether Z7 adopts a stable, compact conformation.

  4. 4.
    Combinatorial optimization into base editor(library_design)

    This stage builds on the loop-engineered scaffold to further improve performance and targeting scope.

    Selection: Combine loop engineering with structure-guided point mutations to further boost activity in an adenine base editor format.

  5. 5.
    Primary human T-cell validation(confirmatory_validation)

    This stage confirms that the engineered editor functions in a therapeutically relevant primary-cell context.

    Selection: Test whether the optimized base editor enables editing in primary human T cells.

  6. 6.
    Cross-scaffold extension to other thermophilic Cas9s(confirmatory_validation)

    This stage tests whether the loop engineering strategy generalizes beyond AtCas9.

    Selection: Apply loop transplantation to GeoCas9 and ThermoCas9 and measure editing efficiency at non-canonical PAMs.

Taxonomy & Function

Primary hierarchy

Mechanism Branch

Architecture: A reusable architecture pattern for arranging parts into an engineered system.

Techniques

No technique tags yet.

Target processes

editingrecombination

Implementation Constraints

cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: sensor

The construct requires the engineered Z7-E78-ABE editor architecture and mammalian-cell base editing assays for use and evaluation.; requires loop engineering combined with structure-guided point mutations; requires adenine base editor architecture

The abstract does not show whether it resolves all specificity, delivery, or safety issues relevant to therapeutic use.; abstract does not specify editing window, byproducts, or off-target profile

Validation

Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication

Supporting Sources

Ranked Claims

Claim 1base editor performancesupports2025Source 1needs review

Z7-E78-ABE achieved a 5.76-fold increase compared to WT AtCas9 and expanded PAM recognition.

The resulting Z7-E78-ABE variant not only achieved a 5.76-fold increase compared to WT AtCas9 and expanded PAM recognition
fold increase vs WT AtCas9 5.76
Claim 2cell type enablementsupports2025Source 1needs review

Z7-E78-ABE enabled editing in primary human T cells, whereas WT AtCas9 did not show editing in that context.

while enabling editing in primary human T cells, which was not observed with WT AtCas9
Claim 3combinatorial engineering effectsupports2025Source 1needs review

Loop engineering can be combined with structure-guided point mutations to further boost Cas9 activity.

Importantly, loop engineering can be combined with structure-guided point mutations to further boost activity.
Claim 4engineering strategy effectsupports2025Source 1needs review

Loop engineering is presented as a streamlined strategy to enhance Cas9 performance.

Here, we present loop engineering as a streamlined strategy to enhance Cas9 performance.
Claim 5generalizabilitysupports2025Source 1needs review

Loop transplantation into GeoCas9 and ThermoCas9 boosted editing efficiency at non-canonical PAMs.

Extending this strategy, loop transplantation into GeoCas9 and ThermoCas9 boosted editing efficiency by a median of 14.50-fold and 7.37-fold, respectively, at non-canonical PAMs.
median fold boost GeoCas9 14.5median fold boost ThermoCas9 7.37
Claim 6mechanistic propertysupports2025Source 1needs review

AtCas9-Z7 maintains high binding affinity under magnesium-limiting conditions.

Z7 maintains high binding affinity under magnesium-limiting condition, a common constraint for Cas9 activity in mammalian cells.
Claim 7overall conclusionsupports2025Source 1needs review

Loop engineering is established as a rational and modular approach for Cas9 optimization with therapeutic potential.

Collectively, these results establish loop engineering as a rational and modular approach for Cas9 optimization with therapeutic potential.
Claim 8structural propertysupports2025Source 1needs review

Molecular dynamics simulations indicate that AtCas9-Z7 adopts a stable, compact conformation.

Molecular dynamics simulations revealed that Z7 adopts a stable, compact conformation.
Claim 9variant performancesupports2025Source 1needs review

AtCas9-Z7 improves nuclease and base editing efficiency relative to AtCas9.

Substituting loops of thermophilic AtCas9 with counterparts from mesophilic Nme1Cas9 generated the AtCas9-Z7 variant, which significantly improves nuclease and base editing efficiency.

Approval Evidence

1 source2 linked approval claimsfirst-pass slug z7-e78-abe
The resulting Z7-E78-ABE variant not only achieved a 5.76-fold increase compared to WT AtCas9 and expanded PAM recognition, while enabling editing in primary human T cells, which was not observed with WT AtCas9.

Source:

base editor performancesupports

Z7-E78-ABE achieved a 5.76-fold increase compared to WT AtCas9 and expanded PAM recognition.

The resulting Z7-E78-ABE variant not only achieved a 5.76-fold increase compared to WT AtCas9 and expanded PAM recognition

Source:

cell type enablementsupports

Z7-E78-ABE enabled editing in primary human T cells, whereas WT AtCas9 did not show editing in that context.

while enabling editing in primary human T cells, which was not observed with WT AtCas9

Source:

Comparisons

Source-stated alternatives

The abstract directly compares this variant to WT AtCas9 and notes a complementary alternative strategy of point-mutation engineering alone.

Source:

The abstract directly compares this variant to WT AtCas9 and notes a complementary alternative strategy of point-mutation engineering alone.

Source-backed strengths

5.76-fold increase compared to WT AtCas9; expanded PAM recognition; enabled editing in primary human T cells

Source:

5.76-fold increase compared to WT AtCas9

Source:

expanded PAM recognition

Source:

enabled editing in primary human T cells

Compared with intron-containing CRISPRa construct

Z7-E78-ABE and intron-containing CRISPRa construct address a similar problem space because they share editing, recombination.

Shared frame: same top-level item type; shared target processes: editing, recombination

Compared with microfluidic organ-on-chip platforms

Z7-E78-ABE and microfluidic organ-on-chip platforms address a similar problem space because they share editing, recombination.

Shared frame: same top-level item type; shared target processes: editing, recombination

Strengths here: looks easier to implement in practice.

Compared with PMNT mixed with single-stranded DNA color reporter

Z7-E78-ABE and PMNT mixed with single-stranded DNA color reporter address a similar problem space because they share editing, recombination.

Shared frame: same top-level item type; shared target processes: editing, recombination

Ranked Citations

  1. 1.
    StructuralSource 1MED2025Claim 1Claim 2Claim 3

    Extracted from this source document.